Elite Pharmaceuticals Inc: Form 10-Q for the period ended Sep 30, 2024
Filed with the SEC on Nov 14, 2024 and accepted by EDGAR at Nov 14, 2024, 16:30 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-07-01 to 2024-09-30 | $18.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2024-04-01 to 2024-09-30 | $37.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2024-07-01 to 2024-09-30 | $10.7m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2024-04-01 to 2024-09-30 | $21.0m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2024-07-01 to 2024-09-30 | $8.2m | us-gaap:GrossProfit |
| Gross profit | 6 months2024-04-01 to 2024-09-30 | $16.7m | us-gaap:GrossProfit |
| Research and development | 3 months2024-07-01 to 2024-09-30 | $2.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2024-04-01 to 2024-09-30 | $4.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2024-07-01 to 2024-09-30 | $3.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2024-04-01 to 2024-09-30 | $7.3m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2024-07-01 to 2024-09-30 | $1.5m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2024-04-01 to 2024-09-30 | $1.7m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-07-01 to 2024-09-30 | −$11.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months2024-04-01 to 2024-09-30 | −$10.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-07-01 to 2024-09-30 | −$0.01 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2024-04-01 to 2024-09-30 | −$0.01 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-07-01 to 2024-09-30 | −$0.01 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2024-04-01 to 2024-09-30 | −$0.01 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-07-01 to 2024-09-30 | 1,068,273,108 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2024-04-01 to 2024-09-30 | 1,068,273,108 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2024-04-01 to 2024-09-30 | $4.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2024-04-01 to 2024-09-30 | $871.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-09-30 | $9.6m | us-gaap:Cash |
| Current assets | At period end2024-09-30 | $45.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-09-30 | $88.2m | us-gaap:Assets |
| Current liabilities | At period end2024-09-30 | $12.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-09-30 | $40.9m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-09-30 | $47.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-24-045933. Last ingested by Listed: Nov 3, 2026, 08:34 ET. Listed shows no prices and gives no investment advice.